ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/08/26	$0.000001	-99.00%	25,000
10/08/26	$0.000100	-.--%	2,349
07/08/26	$0.000100	+9,900.00%	42,067
04/08/26	$0.000001	-99.00%	225

Real-time OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 19:11:19 22/04/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	-.--%		+9,900.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.55M 3.33M 3.04M 5.71M 391M 5.81M 39.01M 15.29M 196M 15.4M 15.06M 653M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.12M -1.05M -959K -1.81M -124M -1.84M -12.33M -4.83M -61.86M -4.87M -4.76M -206M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.35
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-.--%	+9,900.00%	-.--%	-99.80%	11.72K
WUXI APPTEC CO., LTD.	-0.70%	+13.34%	+75.61%	+103.83%	70.85B
ARGENX SE	-2.35%	+2.88%	+35.39%	+64.72%	55.41B
INSMED INCORPORATED	-1.62%	+34.25%	+17.43%	+491.04%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	-1.30%	+11.72%	+53.52%	+6.65%	24.12B
BIONTECH SE	0.00%	+1.59%	-15.06%	-13.21%	23.31B
GENMAB A/S	+0.05%	+6.12%	+46.81%	-21.81%	18.37B
PHARMAESSENTIA CORPORATION	+9.77%	+20.16%	+260.17%	+472.38%	16.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.19%	+7.77%	+31.32%	+626.03%	16.1B
EXELIXIS, INC.	-3.08%	-8.34%	+37.21%	+138.52%	13.12B
Average	+0.10%	+352.67%	+54.24%	+176.84%	26.77B
Weighted average by Cap.	-0.48%	+350.76%	+56.20%	+167.23%

	2021	2022
Net sales	-	19.64M 17.02M 15.93M 14.54M 27.35M 1.87B 27.81M 187M 73.19M 937M 73.73M 72.12M 3.13B
Net income	-58.38M -50.59M -47.36M -43.21M -81.32M -5.57B -82.69M -555M -218M -2.79B -219M -214M -9.3B	-29.88M -25.89M -24.24M -22.12M -41.62M -2.85B -42.32M -284M -111M -1.43B -112M -110M -4.76B
Net Debt	-28.08M -24.33M -22.78M -20.78M -39.11M -2.68B -39.77M -267M -105M -1.34B -105M -103M -4.47B	-5.4M -4.68M -4.38M -4M -7.52M -515M -7.64M -51.34M -20.12M -258M -20.26M -19.82M -860M